Format

Send to

Choose Destination
See comment in PubMed Commons below
J Allergy Clin Immunol. 2005 Jun;115(6):1143-7.

Inhaled LPS induces blood release of Clara cell specific protein (CC16) in human beings.

Author information

1
Clinics of Allergology and Respiratory Diseases, Saint-Pierre University Hospital, Free University of Brussels, Rue Haute 322, B-1000 Brussels, Belgium. omichel@ulb.ac.be

Abstract

BACKGROUND:

Animal models of lung inflammation have validated the plasma 16-kd Clara cell protein (CC16) as a peripheral marker of the permeability of the alveolocapillary barrier.

OBJECTIVE:

We investigated in human beings whether inhaled LPS induced a rise in airways permeability measured by the plasma changes in CC16.

METHODS:

The CC16 was measured in plasma from 15 subjects exposed to LPS by inhalation, during which the kinetics and the dose-response relationship of LPS-induced CC16 were evaluated. Because LPS-induced response involves macrophages activation, the protective effect of oral methylprednisolone was also evaluated.

RESULTS:

An inhalation of 50 microg LPS induced a significant ( P < .001) rise in CC16 after 6 hours (from 7.24 [+/-0.68] microg/L to 10.69 [+/-0.99] microg/L) that normalized at 24 hours (6.65 [+/-0.33] microg/L). The CC16 response was dose-related, with the no-response threshold 0.5 microg LPS. A 6-day treatment with 20 mg/d methylprednisolone inhibited significantly ( P < .001) the CC16 response to 50 microg LPS.

CONCLUSION:

Exposure to LPS by inhalation in healthy subjects induces an intravascular leakage of CC16 that can be blocked by corticosteroids. These observations further validate plasma CC16 as a noninvasive test of the alveolocapillary barrier permeability.

PMID:
15940126
DOI:
10.1016/j.jaci.2005.01.067
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center